Zubsolv receives authorization for Treatment of Opioid Dependence in Europe
Orexo AB (publ.) announce that the European Medicines Agency (EMA) has granted a Marketing Authorization (MA) for Zubsolv (buprenorphine and naloxone), a novel rapidly-disintegrating…
Read More...
Read More...
